Sara Al-Noor, Tasneem Labak, Adam Bakos, Kaitlin Ferraro, Tejas Patel, Noah Cleary Tasneem Labak Glioblastoma (GBM) is the most common and lethal primary malignant brain cancer. Despite standard treatments, the average life expectancy is only about 15 months, and majority of patients experience recurrence of this aggressive cancer within a couple years of their initial […]
Interview With Dr. Lisa Porter: Advancing Breakthroughs in Cancer Research and Health Innovation Facebook X Email WhatsApp Reddit Print
Advancing Breakthroughs in Cancer Research and Health Innovation Read More »
Our names are Jeffery Martin and Vanessa Riolo, and we are the Porter lab’s Green Lab Ambassadors! Together with Dr. Fidalgo, our Green Lab representative, and Dr. Porter’s full support, we are very excited to share more about sustainability initiatives and the various steps our lab is actively taking to reduce our environmental impact and
From the Bench to Helping the Planet: Going Green for a Better Future Read More »
My name is Jeffery Martin, and I am a second-year Master’s student working on the prostate cancer project in Dr. Porter’s lab in the Biomedical Science Department at the University of Windsor. In honour of Prostate Cancer Awareness Month, I would like to share some of the exciting prostate cancer research happening at the University
Groundbreaking Prostate Cancer Research at the University of Windsor Read More »
Christopher Jaworski Christopher Jaworski Glioblastoma (GBM) stands as one of the most lethal and aggressive brain cancers, often defying current treatment strategies. The outlook for patients remains grim, with average survival hovering around just 14 months after diagnosis. A major reason for this is the tumor’s ability to resist therapy and recur, often driven by
Stephanie Dinescu Glioblastoma (GBM) is the most frequent and aggressive primary malignant brain tumour. Despite rigorous therapeutic efforts, the prognosis of GBM remains extremely low, with a median survival of approximately 14 months after diagnosis. Our lab studies a cyclin-like protein called Spy1 which has been found to be elevated in GBM. Spy1 overrides cell-cycle checkpoints
Amy Llancari My project focuses on differentiating the progression of Non-alcoholic Fatty Liver Disease (NALFD) into Hepatocellular Carcinoma (HCC) between male and female mice. HCC is the sixth most prevalent cancer in the world, yet it ranks as the third leading type of cancer deaths with an accelerated increase in incidence rates. NAFLD is a
Tiana Visconti Determining the Dependency of Spy1 based on Rb Status in Triple Negative Breast Cancer Breast cancer is the second most common cancer worldwide and the most common cancer among women. Triple Negative Breast Cancer (TNBC) is a particularly aggressive form of breast cancer with many subtypes based on gene expression profiles. There
Undergrads 2022 – part 3 Read More »
Ali Nadi Applying CRISPR/Cas9 and Fluorescent Tools to Dissect the Role of Tuberin in Cell Cycle Regulation How cells regulate their growth and division involves a tightly controlled integration of many mechanisms. In cells, Tuberin (gene – TSC2) is a protein in the Tuberous Sclerosis Complex (TSC) which modulates cellular growth, size, and proliferation. Mutations in
Undergrads 2022 – part 2 Read More »
No position is available at the moment.
For interested graduate students please visit the University of Windsor Department of Biology for admission requirements (http://www1.uwindsor.ca/biology/graduate-program) and contact Dr Bre-Anne Fifield (fifield@uwindsor.ca) to express your interest in joining the lab.
For volunteers please contact Dr Dorota Lubanska (lubanskd@uwindsor.ca) and indicate the year you are in and the type of experience you are interested in. Note that interviews only happen once a year in the Spring.
Please click on the link below:
http://windsorcancerresearch.com/research/application-of-interest-in-cancer-research/